

January 29, 2019

Shalby/SE/2017-18/92

The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400 051.

Scrip Code : SHALBY

Through : <https://www.connect2nse.com/LISTING/>

Corporate Service Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

Scrip Code: 540797

Through : <http://listing.bseindia.com>

Sub: Investor Presentation for the Third Quarter ended 31st December 2018 -disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the SEBI LODR")

Dear Sir / Madam,

We are submitting herewith Investor Presentation on financial & operational performance of the Company for third quarter ended 31st December 2018, which is also being made available on our website.

We request to take the same on your records and disseminate the same to the members.

Thanking you,

Yours sincerely,
For **Shalby Limited**

Jayesh Patel
Company Secretary & Compliance Officer


Encl.: as above

SHALBY LIMITED

Regd. Office: Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India.


Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org

CIN: L85110GJ2004PLC044667



Investor Presentation

Q3 FY 19



Important Disclosure

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements”, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions in India. This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.

*...because **passion** drives perfection...*

*...and **perfection** drives
performance*



Current Scale of Operations

11 Hospitals

2,012* Total Bed Capacity

1,102** Operational beds

887 Census Beds

165 Non Census Beds

404 Doctors & **3,000+** Support Staff

55% Operating bed to total bed capacity

45% Bed Occupancy (based on census beds)

31% 11 year CAGR Revenue

40% 11 year CAGR EBITDA

 Double-digit return ratios against industry trend of single-digit

 Consistently superior ROCE of mature hospitals

* Maximum number of beds according to structure of the hospital


**The operational bed count of 1,102 considers 50 operational beds at Zynova-Shalby Hospital, Mumbai, for which no other operational parameters are tracked




Decadal track record

Best in class financials

Revenue





EBITDA



Growth achieved without any outside equity funding till FY 17


Best in class economic returns




- Double Digit return ratios against industry trend of single digit due to our unique business model

IP and OP Count (Yearly Trend)

IP Count




OP Count




IP and OP Count (Quarterly Trend)

IP Count




OP Count




Surgeries Count (Yearly Trend)

Surgeries Count: Arthroplasty vs Others




Surgeries Count (Yearly Trend)

Arthroplasty Vs Others




Surgeries Count (Quarterly Trend)



Surgeries - Arthroplasty vs Others



Surgeries Count (Quarterly Trend)

Arthroplasty Vs Others





Performance Q3FY19

Key Achievements of the Quarter

Awarded Medical Value Travel Specialist Hospital Award 2018 in “Orthopaedics - Joint Replacement” instituted by Ministry of Commerce and Industry and FICCI

Awarded best “Medical Tourism in Gujarat Award” consecutively for 3rd year.

Successfully carried out surgery on 5 month old suffering from Pulmonary Atresia at Indore Unit

Mohali unit successfully broken even at EBITDA level.

Performance Synopsis

(INR in million)

Particulars	Quarter Ended 31/12/2018	% of Revenue	Quarter Ended 31/12/2017	% of Revenue	Growth
Total Revenue	1,151.1		1,013.1		14%
EBITDA	213.3	19%	250.8	25%	-15%
Bed Capacity (Nos.)	2012		2012		0%
Operational Beds (Nos.)	1,102		951		16%
Average Length of Stay(Days)	2.67		3.75		29%
Occupancy (Beds)	397		358		11%
In-Patient Count (Nos.)	13,642		8,788		55%
Out patient Count (Nos.)	71,738		55,271		30%
Surgeries Count	4,638		4,619		0%
ARPOB (In Rs.)	31,517		30,760		2%

Note: The operational bed count of 1,102 considers 50 operational beds at Zynova-Shalby Hospital, Mumbai, for which no other operational parameters are tracked


Financial Highlights Q3FY19 Standalone

(INR in million)

Particulars	Quarter Ended 31/12/2018	% of Revenue	Quarter Ended 31/12/2017	% of Revenue	Growth
Revenue from Operations	1131.4		966.6		17.1%
Other Income	19.7		46.5		-57.7%
Total Income	1151.1		1013.1		13.6%
Expenses					
Materials & Consumables	298.5	25.9%	280.8	27.7%	
Fees to Doctors and Consultants	311.0	27.0%	215.5	21.3%	
Other Operative Expenses	35.3	3.1%	30.9	3.0%	
Employee Costs	215.8	18.7%	164.8	16.3%	
Administrative Expenses	58.7	5.1%	58.8	5.8%	
Advt & Promotion	18.5	1.6%	11.5	1.1%	
Total Operational Expenses	937.8	81.5%	762.3	75.2%	
EBITDA	213.3	18.5%	250.8	24.8%	-14.9%
Finance Cost	14.6		34.4		
Depreciation & Amortization Expense	85.2		66.7		
Profit before tax (PBT)	113.5		149.7		-24.2%
Tax Expense	-15.4		44.86		
Profit after tax (PAT)	128.9	11.2%	104.9	10.4%	22.9%


Financials Parameters

(INR in million)



- Total Revenue has increased by 13.6% on Year on Year basis
- EBITDA for Q3 FY 19 has decreased by 14.9% compared to Q3 FY 18 as Doctor cost has increased by 44.3% and Employee cost has increased by 31%
- PAT for Q3 FY 19 has increased by 22.9% on Year on Year basis


ARPOB and ALOS



- Change in ALOS is a result of increase in operational excellence as a continuous process as well as increased multi-specialty focus including specialties like Oncology, Nephrology, Cardiac Sciences etc. which has large number of day care procedures


Revenue Mix Q3FY19

Specialty Mix



- Arthroplasty
- Cardiac Science
- Other Ortho
- Nephrology
- Critical Care & General Medicine
- Oncology
- Neurology
- Others

Payer Profile




- Self Pay
- Corporate Government
- TPA
- Corporate Private


Surgery Count and Cost Structure Q3FY19

Cost Structure

Surgery Count




- Arthroplasty
- Orthopaedic
- General Surgery
- Nephrology
- Gynecology & IVF
- Cosmetic & Plastic Surgery
- Oncology
- Others



- Total Cost
- Advertising and Promotion
- Administrative Expenses
- Employee Cost
- Other Operative Expenses
- Fees to Doctors and Consultants
- Materials & Consumables

Bed Count Split





















Maturity Profile - Q3FY19

Maturity Profile	Avg. Occupied Beds	Census Beds	Non-Census Beds	Operational Beds	Non-Operational Beds	Total Bed Capacity
4 years + (SG; Vijay; Krishna; Vapi)	149	325 + 57 = 382	57	382 + 212 = 594	212	594
2-4 years (Jabalpur, Indore)	120	309 + 52 = 361	52	361 + 115 = 476	115	476
< 2 years (Jaipur; Naroda; Surat; Mohali)	128	253 + 56 = 309	56	309 + 583 = 892	583	892
Total	397	887	165	1,102*	910	2,012

Note: The operational bed count of 1,102 considers 50 operational beds at Zynova-Shalby Hospital, Mumbai, for which no other operational parameters are tracked

Maturity Profile - Q3FY19 - with Revenue mix

Maturity Profile	% of Total Revenue	Arthroplasty	Non Arthroplasty	ARPOB(Rs)	ALOS(Days)	EBITDA %
4 years + (SG; Vijay; Krishna; Vapi)	 50%	 30%	 20%	 41,629	 3.73	 29.7%
2-4 years (Jabalpur, Indore)	 22%	 4%	 18%	 22,861	 3.38	 6.5%
< 2 years (Jaipur; Naroda; Surat; Mohali)	 28%	 9%	 19%	 27,952	 1.75	 8.2%
Total	100%	43%	57%	31,517	2.67	18.5%

Maturity Profile - Q3 FY19 vs Q3 FY18 - Operational Parameters

Q3 FY 19


Maturity Profile	IP Count	OP Count	Surgery Count
4 years + (SG; Vijay; Krishna; Vapi)	3,673	26,955	2,531
2-4 years (Jabalpur, Indore)	3,265	21,887	976
< 2 years (Jaipur; Naroda; Surat; Mohali)	6,704	22,896	1,131
Total	13,642	71,738	4,638

Q3 FY 18

Maturity Profile	IP Count	OP Count	Surgery Count
4 years + (SG; Vijay; Krishna; Vapi)	4,006	26,665	3,150
2-4 years (Jabalpur, Indore)	3,180	18,994	803
< 2 years (Jaipur; Naroda; Surat; Mohali)	1,602	9,612	666
Total	8,788	55,271	4,619

Shareholding Pattern

Shareholding as on 31st December 2018



• Total Number of Shares: 108,009,770

Our Strengths and Differentiators

Experienced promoters with hands-on involvement

Strong brand, global leadership in Joint Replacement

Optimized Business Model now being replicated

Increasing focus on Quaternary treatments such as Oncology and Organ transplants

Even after the IPO promoter holding is ~80%

Unleveraged Balance Sheet

Strong emphasis on governance and compliance

Leadership and succession plan in place

Detailed Information

For more detailed information please click on the link below:

- [Q3FY19 result](#)
- [Q2FY19 result](#)
- [Q1FY19 result](#)
- [Monitoring Agency Report for IPO proceeds](#)
- [FY18 result](#)

Thank you



SHALBY LIMITED

Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000
Fax: +91 79 4020 3120 | Website: www.shalby.org | CIN: L85110GJ2004PLC044667

Script code: BSE: 540797 | NSE: SHALBY